REFERENCES
1. Lee SH, Ripke S, Neale BM, et al. Cross-Disorder Group of the Psychiatric Genomics Consortium; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013;45:984-94.
2. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013;381:1371-9.
4. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 2019;179:1469-82.e11.
5. Smeland OB, Bahrami S, Frei O, et al. Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. Mol Psychiatry 2020;25:844-53.
6. Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research review: polygenic methods and their application to psychiatric traits. J Child Psychol Psychiatry 2014;55:1068-87.
7. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421-7.
8. Wray NR, Ripke S, Mattheisen M, et al. Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 2018;50:668-81.
9. Grove J, Ripke S, Als TD, et al. Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium; BUPGEN; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium; 23andMe Research Team. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet 2019;51:431-44.
10. Stahl EA, Breen G, Forstner AJ, et al. Bipolar Disorder Working Group of the Psychiatric Genomics Consortium. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet 2019;51:793-803.
11. Demontis D, Walters RK, Martin J, et al. ADHD Working Group of the Psychiatric Genomics Consortium (PGC); Early Lifecourse & Genetic Epidemiology (EAGLE) Consortium; 23andMe Research Team. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet 2019;51:63-75.
12. Uher R, Zwicker A. Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness. World Psychiatry 2017;16:121-9.
13. Yamamoto KR. Steroid receptor regulated transcription of specific genes and gene networks. Annu Rev Genet 1985;19:209-52.
14. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
17. Eyles DW, Trzaskowski M, Vinkhuyzen AAE, et al. The association between neonatal vitamin D status and risk of schizophrenia. Sci Rep 2018;8:17692.
18. Arloth J, Bogdan R, Weber P, et al. Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (PGC); Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium PGC. Genetic differences in the immediate transcriptome response to stress predict risk-related brain function and psychiatric disorders. Neuron 2015;86:1189-202.
19. Lee BK, Eyles DW, Magnusson C, et al. Developmental vitamin D and autism spectrum disorders: findings from the Stockholm Youth Cohort. Mol Psychiatry 2021;26:1578-88.
20. Zagni E, Simoni L, Colombo D. Sex and gender differences in central nervous system-related disorders. Neurosci J 2016;2016:2827090.
22. McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res 2011;45:1027-35.
23. Riecher-rössler A. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry 2017;4:63-72.
25. Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry 2017;4:146-58.
26. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008;33:693-710.
27. Shi L, Lu ZA, Que JY, et al. Prevalence of and risk factors associated with mental health symptoms among the general population in China during the Coronavirus Disease 2019 Pandemic. JAMA Netw Open 2020;3:e2014053.
28. Reay WR, Cairns MJ. The role of the retinoids in schizophrenia: genomic and clinical perspectives. Mol Psychiatry 2020;25:706-18.
29. Bao Y, Ibram G, Blaner WS, et al. Low maternal retinol as a risk factor for schizophrenia in adult offspring. Schizophr Res 2012;137:159-65.
30. Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol 2005;75:275-93.
32. Stanikova D, Luck T, Bae YJ, et al. Increased estrogen level can be associated with depression in males. Psychoneuroendocrinology 2018;87:196-203.
33. Huber T, Rollnik J, Wilhelms J, von zur Mühlen A, Emrich H, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001;26:27-35.
34. Brzezinski-Sinai NA, Brzezinski A. Schizophrenia and sex hormones: what is the link? Front Psychiatry 2020;11:693.
35. Hwang WJ, Lee TY, Kim NS, Kwon JS. The role of estrogen receptors and their signaling across psychiatric disorders. Int J Mol Sci 2020;22:373.
36. Bernal J. Thyroid hormones in brain development and function. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25905404. [Last accessed on 7 Jun 2021].
38. Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 2014;44:797-810.
39. Berger M, Nelson B, Markulev C, et al. Relationship between polyunsaturated fatty acids and psychopathology in the NEURAPRO clinical trial. Front Psychiatry 2019;10:393.
40. Amminger GP, McGorry PD. Update on ω-3 polyunsaturated fatty acids in early-stage psychotic disorders. Neuropsychopharmacology 2012;37:309-10.
41. Olivares AM, Moreno-Ramos OA, Haider NB. Role of nuclear receptors in central nervous system development and associated diseases. J Exp Neurosci 2015;9:93-121.
42. Ferrara SJ, Scanlan TS. A CNS-targeting prodrug strategy for nuclear receptor modulators. J Med Chem 2020;63:9742-51.
43. Mackeh R, Marr AK, Dargham SR, Syed N, Fakhro KA, Kino T. Single-nucleotide variations of the human nuclear hormone receptor genes in 60,000 individuals. J Endocr Soc 2018;2:77-90.
44. Achermann JC, Schwabe J, Fairall L, Chatterjee K. Genetic disorders of nuclear receptors. J Clin Invest 2017;127:1181-92.
45. Guissart C, Latypova X, Rollier P, et al. Dual molecular effects of dominant RORA mutations cause two variants of syndromic intellectual disability with either autism or cerebellar ataxia. Am J Hum Genet 2018;102:744-59.
46. Rudolf G, Lesca G, Mehrjouy MM, et al. Loss of function of the retinoid-related nuclear receptor (RORB) gene and epilepsy. Eur J Hum Genet 2016;24:1761-70.
47. Millard CJ, Watson PJ, Fairall L, Schwabe JW. An evolving understanding of nuclear receptor coregulator proteins. J Mol Endocrinol 2013;51:T23-36.
48. Malovannaya A, Lanz RB, Jung SY, et al. Analysis of the human endogenous coregulator complexome. Cell 2011;145:787-99.
49. Broekema MF, Hollman DAA, Koppen A, et al. Profiling of 3696 nuclear receptor-coregulator interactions: a resource for biological and clinical discovery. Endocrinology 2018;159:2397-407.
50. Tagami T, Madison LD, Nagaya T, Jameson JL. Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone. Mol Cell Biol 1997;17:2642-8.
51. Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, Saatcioglu F. Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a negative hormone response element. J Biol Chem 2002;277:49517-22.
52. Tora L, Gronemeyer H, Turcotte B, Gaub MP, Chambon P. The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 1988;333:185-8.
53. Shao D, Lazar MA. Modulating nuclear receptor function: may the phos be with you. J Clin Invest 1999;103:1617-8.
54. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev 2007;28:575-87.
55. Kong Y, Zhou W, Sun Z. Nuclear receptor corepressors in intellectual disability and autism. Mol Psychiatry 2020;25:2220-36.
56. Tabet AC, Leroy C, Dupont C, et al. De novo deletion of TBL1XR1 in a child with non-specific developmental delay supports its implication in intellectual disability. Am J Med Genet A 2014;164A:2335-7.
57. Vaqueiro AC, de Oliveira CP, Cordoba MS, et al. Expanding the spectrum of TBL1XR1 deletion: report of a patient with brain and cardiac malformations. Eur J Med Genet 2018;61:29-33.
58. Sakaguchi Y, Uehara T, Suzuki H, et al. Haploinsufficiency of NCOR1 associated with autism spectrum disorder, scoliosis, and abnormal palatogenesis. Am J Med Genet A 2018;176:2466-9.
59. Zhou W, He Y, Rehman AU, et al. DDD study. Author correction: loss of function of NCOR1 and NCOR2 impairs memory through a novel GABAergic hypothalamus-CA3 projection. Nat Neurosci 2019;22:1533.
60. Sajan SA, Jhangiani SN, Muzny DM, et al. Enrichment of mutations in chromatin regulators in people with Rett syndrome lacking mutations in MECP2. Genet Med 2017;19:13-9.
61. Reay WR, Atkins JR, Quidé Y, Carr VJ, Green MJ, Cairns MJ. Polygenic disruption of retinoid signalling in schizophrenia and a severe cognitive deficit subtype. Mol Psychiatry 2020;25:719-31.
62. Viosca J, Lopez-Atalaya JP, Olivares R, Eckner R, Barco A. Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology. Neurobiol Dis 2010;37:186-94.
63. Qvist P, Christensen JH, Vardya I, et al. The schizophrenia-associated BRD1 gene regulates behavior, neurotransmission, and expression of schizophrenia risk enriched gene sets in mice. Biol Psychiatry 2017;82:62-76.
64. Rajkumar AP, Qvist P, Donskov JG, et al. Reduced Brd1 expression leads to reversible depression-like behaviors and gene-expression changes in female mice. Transl Psychiatry 2020;10:239.
65. Qvist P, Eskildsen SF, Hansen B, et al. Brain volumetric alterations accompanied with loss of striatal medium-sized spiny neurons and cortical parvalbumin expressing interneurons in Brd1+/- mice. Sci Rep 2018;8:16486.
66. Oliveira AM, Estévez MA, Hawk JD, Grimes S, Brindle PK, Abel T. Subregion-specific p300 conditional knock-out mice exhibit long-term memory impairments. Learn Mem 2011;18:161-9.
67. Valor LM, Pulopulos MM, Jimenez-Minchan M, Olivares R, Lutz B, Barco A. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability. J Neurosci 2011;31:1652-63.
68. Zhang Z, Hofmann C, Casanova E, Schütz G, Lutz B. Generation of a conditional allele of the CBP gene in mouse. Genesis 2004;40:82-9.
69. Morimoto Y, Ono S, Yoshida S, et al. A unique missense variant in the E1A-binding protein P400 gene is implicated in schizophrenia by whole-exome sequencing and mutant mouse models. Transl Psychiatry 2021;11:132.
70. Ripke S, Walters JTR, O’Donovan MC. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. medRxiv 2020; doi: 10.1101/2020.09.12.20192922.
71. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452-8.
72. Cai L, Wheeler E, Kerrison ND, et al. Genome-wide association analysis of type 2 diabetes in the EPIC-InterAct study. Sci Data 2020;7:393.
73. Shah S, Henry A, Roselli C, et al. Regeneron Genetics Center. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun 2020;11:163.
74. Yengo L, Sidorenko J, Kemper KE, et al. GIANT Consortium. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. Hum Mol Genet 2018;27:3641-9.
75. Leslie R, O'Donnell CJ, Johnson AD. GRASP: analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database. Bioinformatics 2014;30:i185-94.
76. Lam M, Awasthi S, Watson HJ, et al. RICOPILI: rapid imputation for COnsortias PIpeLIne. Bioinformatics 2020;36:930-3.
77. Singh T, Kurki MI, Curtis D, et al. Swedish Schizophrenia Study; INTERVAL Study; DDD Study; UK10 K Consortium. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 2016;19:571-7.
78. Satterstrom FK, Kosmicki JA, Wang J, et al. Autism Sequencing Consortium; iPSYCH-Broad Consortium. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 2020;180:568-84.e23.
79. Hannon E, Dempster E, Viana J, et al. An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation. Genome Biol 2016;17:176.
80. Aberg KA, McClay JL, Nerella S, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry 2014;71:255-64.
81. Chan RF, Shabalin AA, Montano C, et al. Independent methylome-wide association studies of schizophrenia detect consistent case-control differences. Schizophr Bull 2020;46:319-27.
82. Aberg KA, Dean B, Shabalin AA, et al. Methylome-wide association findings for major depressive disorder overlap in blood and brain and replicate in independent brain samples. Mol Psychiatry 2020;25:1344-54.
83. van Dongen J, Zilhão NR, Sugden K, et al. BIOS Consortium. Epigenome-wide Association Study of Attention-Deficit/Hyperactivity Disorder Symptoms in Adults. Biol Psychiatry 2019;86:599-607.
84. Walton E, Pingault JB, Cecil CA, et al. Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study. Mol Psychiatry 2017;22:250-6.
85. Hannon E, Schendel D, Ladd-Acosta C, et al. iPSYCH-Broad ASD Group. Elevated polygenic burden for autism is associated with differential DNA methylation at birth. Genome Med 2018;10:19.
86. Spiers H, Hannon E, Schalkwyk LC, et al. Methylomic trajectories across human fetal brain development. Genome Res 2015;25:338-52.
87. Miller JA, Ding SL, Sunkin SM, et al. Transcriptional landscape of the prenatal human brain. Nature 2014;508:199-206.
88. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol 2015;11:e1004219.
89. Kulakovskiy IV, Vorontsov IE, Yevshin IS, et al. HOCOMOCO: towards a complete collection of transcription factor binding models for human and mouse via large-scale ChIP-Seq analysis. Nucleic Acids Res 2018;46:D252-9.
90. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics 2011;27:1017-8.
91. Shen L, Sinai M. GeneOverlap: Test and visualize gene overlaps. R package version 1.2.0. 2013. Available from: http://shenlab-sinai.github.io/shenlab-sinai/. [Last accessed on 7 Jun 2021].
92. Hoffman GE, Bendl J, Voloudakis G, et al. CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder. Sci Data 2019;6:180.
93. Gearing LJ, Cumming HE, Chapman R, et al. CiiiDER: A tool for predicting and analysing transcription factor binding sites. PLoS One 2019;14:e0215495.
94. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res 2015;43:W566-70.
95. McKenzie AT, Wang M, Hauberg ME, et al. Brain cell type specific gene expression and co-expression network architectures. Sci Rep 2018;8:8868.
96. Shi L, Zhang Z, Su B. Sex biased gene expression profiling of human brains at major developmental stages. Sci Rep 2016;6:21181.
97. Buroker NE, Young ME, Wei C, et al. The dominant negative thyroid hormone receptor beta-mutant {Delta}337T alters PPAR{alpha} signaling in heart. Am J Physiol Endocrinol Metab 2007;292:E453-60.
98. Swanson HI, Wada T, Xie W, et al. Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos 2013;41:1-11.
99. Liu S, Downes M, Evans RM. Metabolic regulation by nuclear receptors. In: Nakao K, Minato N, Uemoto S, editors. Innovative medicine. Tokyo: Springer Japan; 2015. p. 25-37.
100. Moutinho M, Landreth GE. Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. J Lipid Res 2017;58:1937-49.
101. Fitz NF, Nam KN, Koldamova R, Lefterov I. Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease. Br J Pharmacol 2019;176:3599-610.
102. Corredor B, Dattani M, Gertosio C, Bozzola M. Tall stature: a challenge for clinicians. Curr Pediatr Rev 2019;15:10-21.
103. De Magalhaes Filho CD, Downes M, Evans RM. Farnesoid X receptor an emerging target to combat obesity. Dig Dis 2017;35:185-90.
104. Skerrett R, Malm T, Landreth G. Nuclear receptors in neurodegenerative diseases. Neurobiol Dis 2014;72 Pt A:104-16.
105. Rees E, Owen MJ. Translating insights from neuropsychiatric genetics and genomics for precision psychiatry. Genome Med 2020;12:43.
106. Owen MJ, O'Donovan MC. Schizophrenia and the neurodevelopmental continuum:evidence from genomics. World Psychiatry 2017;16:227-35.
107. Aberg KA, Xie LY, McClay JL, et al. Testing two models describing how methylome-wide studies in blood are informative for psychiatric conditions. Epigenomics 2013;5:367-77.
108. Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008;82:696-711.
109. Ladd-Acosta C, Hansen KD, Briem E, Fallin MD, Kaufmann WE, Feinberg AP. Common DNA methylation alterations in multiple brain regions in autism. Mol Psychiatry 2014;19:862-71.
110. Starnawska A, Tan Q, McGue M, et al. Epigenome-wide association study of cognitive functioning in middle-aged monozygotic twins. Front Aging Neurosci 2017;9:413.
111. Ianov L, Riva A, Kumar A, Foster TC. DNA methylation of synaptic genes in the prefrontal cortex is associated with aging and age-related cognitive impairment. Front Aging Neurosci 2017;9:249.
112. Vogel Ciernia A, LaSalle J. The landscape of DNA methylation amid a perfect storm of autism aetiologies. Nat Rev Neurosci 2016;17:411-23.
113. Montano C, Taub MA, Jaffe A, et al. Association of DNA methylation differences with schizophrenia in an epigenome-wide association study. JAMA Psychiatry 2016;73:506-14.
114. Córdova-Palomera A, Fatjó-Vilas M, Gastó C, Navarro V, Krebs MO, Fañanás L. Genome-wide methylation study on depression: differential methylation and variable methylation in monozygotic twins. Transl Psychiatry 2015;5:e557.
115. Palma-Gudiel H, Córdova-Palomera A, Eixarch E, Deuschle M, Fañanás L. Maternal psychosocial stress during pregnancy alters the epigenetic signature of the glucocorticoid receptor gene promoter in their offspring: a meta-analysis. Epigenetics 2015;10:893-902.
116. Chen S, Mukherjee N, Janjanam VD, et al. Consistency and variability of DNA methylation in women during puberty, young adulthood, and pregnancy. Genet Epigenet 2017;9:1179237X17721540.
117. Lomniczi A, Loche A, Castellano JM, et al. Epigenetic control of female puberty. Nat Neurosci 2013;16:281-9.
119. Corley SM, Tsai SY, Wilkins MR, Shannon Weickert C. Transcriptomic analysis shows decreased cortical expression of NR4A1, NR4A2 and RXRB in schizophrenia and provides evidence for nuclear receptor dysregulation. PLoS One 2016;11:e0166944.
120. Maire A, Teyssier C, Balaguer P, Bourguet W, Germain P. Regulation of RXR-RAR heterodimers by RXR- and RAR-specific ligands and their combinations. Cells 2019;8:1392.
121. Penvose A, Keenan JL, Bray D, Ramlall V, Siggers T. Comprehensive study of nuclear receptor DNA binding provides a revised framework for understanding receptor specificity. Nat Commun 2019;10:2514.
122. Lenroot RK, Gogtay N, Greenstein DK, et al. Sexual dimorphism of brain developmental trajectories during childhood and adolescence. Neuroimage 2007;36:1065-73.
123. Marrocco J, McEwen BS. Sex in the brain: hormones and sex differences. Dialogues Clin Neurosci 2017;18:373-83.
124. Hu VW, Sarachana T, Sherrard RM, Kocher KM. Investigation of sex differences in the expression of RORA and its transcriptional targets in the brain as a potential contributor to the sex bias in autism. Mol Autism 2015;6:7.
125. Lenroot RK, Giedd JN. The changing impact of genes and environment on brain development during childhood and adolescence: initial findings from a neuroimaging study of pediatric twins. Dev Psychopathol 2008;20:1161-75.
126. Ahmed OM, El-Gareib AW, El-Bakry AM, Abd El-Tawab SM, Ahmed RG. Thyroid hormones states and brain development interactions. Int J Dev Neurosci 2008;26:147-209.
127. Herzmann C, Torrens JK. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999;341:2015.
128. Zoeller RT, Rovet J. Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. J Neuroendocrinol 2004;16:809-18.
129. Pertile RA, Cui X, Eyles DW. Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience 2016;333:193-203.
130. Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396-402.
131. Baron-Cohen S, Auyeung B, Nørgaard-Pedersen B, et al. Elevated fetal steroidogenic activity in autism. Mol Psychiatry 2015;20:369-76.
132. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
133. Xu D, Huang S, Wang H, Xie W. Regulation of brain drug metabolizing enzymes and transporters by nuclear receptors. Drug Metab Rev 2018;50:407-14.
134. Erk S, Mohnke S, Ripke S, et al. Functional neuroimaging effects of recently discovered genetic risk loci for schizophrenia and polygenic risk profile in five RDoC subdomains. Transl Psychiatry 2017;7:e997.
135. Hukkanen J, Hakkola J, Rysä J. Pregnane X receptor (PXR)--a contributor to the diabetes epidemic? Drug Metabol Drug Interact 2014;29:3-15.
136. Gao J, He J, Zhai Y, Wada T, Xie W. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J Biol Chem 2009;284:25984-92.
137. Cipolletta D, Feuerer M, Li A, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012;486:549-53.
138. Dalgård C, Petersen MS, Weihe P, Grandjean P. Vitamin D status in relation to glucose metabolism and type 2 diabetes in septuagenarians. Diabetes Care 2011;34:1284-8.
139. Cummings JL, Zhong K, Kinney JW, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. Alzheimers Res Ther 2016;8:4.
140. Gordon JL, Peltier A, Grummisch JA, Sykes Tottenham L. Estradiol fluctuation, sensitivity to stress, and depressive symptoms in the menopause transition: a pilot study. Front Psychol 2019;10:1319.
141. Thomas N, Gurvich C, Hudaib AR, Gavrilidis E, Kulkarni J. Dissecting the syndrome of schizophrenia: associations between symptomatology and hormone levels in women with schizophrenia. Psychiatry Res 2019;280:112510.
142. Dwyer JB, Aftab A, Radhakrishnan R, et al. APA Council of Research Task Force on Novel Biomarkers and Treatments. Hormonal treatments for major depressive disorder: state of the art. Am J Psychiatry 2020;177:686-705.
143. Meinhard N, Kessing LV, Vinberg M. The role of estrogen in bipolar disorder, a review. Nord J Psychiatry 2014;68:81-7.
144. de Boer J, Prikken M, Lei WU, Begemann M, Sommer I. The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis. NPJ Schizophr 2018;4:1.
145. Popovic D, Schmitt A, Kaurani L, et al. Childhood trauma in schizophrenia: current findings and research perspectives. Front Neurosci 2019;13:274.
146. Aas M, Henry C, Andreassen OA, Bellivier F, Melle I, Etain B. The role of childhood trauma in bipolar disorders. Int J Bipolar Disord 2016;4:2.
147. ter Heegde F, De Rijk RH, Vinkers CH. The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology 2015;52:92-110.
148. Endedijk HM, Nelemans SA, Schür RR, et al. The role of stress and mineralocorticoid receptor haplotypes in the development of symptoms of depression and anxiety during adolescence. Front Psychiatry 2020;11:367.
149. Vinkers CH, Joëls M, Milaneschi Y, et al. Mineralocorticoid receptor haplotypes sex-dependently moderate depression susceptibility following childhood maltreatment. Psychoneuroendocrinology 2015;54:90-102.
150. Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to ppars and other nuclear receptors. Genes Nutr 2006;1:95-106.
151. Lengqvist J, Mata De Urquiza A, Bergman AC, et al. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain. Mol Cell Proteomics 2004;3:692-703.
152. van Neerven S, Kampmann E, Mey J. RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases. Prog Neurobiol 2008;85:433-51.
153. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007;152:576-82.
154. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008;13:264-75.
155. Velmeshev D, Schirmer L, Jung D, et al. Single-cell genomics identifies cell type-specific molecular changes in autism. Science 2019;364:685-9.
156. Sarachana T, Hu VW. Genome-wide identification of transcriptional targets of RORA reveals direct regulation of multiple genes associated with autism spectrum disorder. Mol Autism 2013;4:14.
157. Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov 2014;13:197-216.
158. Nguyen A, Rauch TA, Pfeifer GP, Hu VW. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. FASEB J 2010;24:3036-51.
159. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal 2009;7:e003.
160. Grayaa S, Zerbinati C, Messedi M, et al. Plasma oxysterol profiling in children reveals 24-hydroxycholesterol as a potential marker for Autism Spectrum Disorders. Biochimie 2018;153:80-5.
161. de Vera IM, Giri PK, Munoz-Tello P, et al. Identification of a binding site for unsaturated fatty acids in the orphan nuclear receptor nurr1. ACS Chem Biol 2016;11:1795-9.
162. Willems S, Kilu W, Ni X, et al. The orphan nuclear receptor Nurr1 is responsive to non-steroidal anti-inflammatory drugs. Commun Chem 2020;3:85.
163. Pan T, Zhu W, Zhao H, et al. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res 2008;1222:222-9.
164. Decressac M, Volakakis N, Björklund A, Perlmann T. NURR1 in Parkinson disease--from pathogenesis to therapeutic potential. Nat Rev Neurol 2013;9:629-36.
165. Zhou J, Oakley RH, Cidlowski JA. DAX-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X-chromosome, gene 1) selectively inhibits transactivation but not transrepression mediated by the glucocorticoid receptor in a LXXLL-dependent manner. Mol Endocrinol 2008;22:1521-34.
166. Obradović D, Tirard M, Némethy Z, Hirsch O, Gronemeyer H, Almeida OF. DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells--toward a basis for the opposite actions elicited by two nuclear receptors? Mol Pharmacol 2004;65:761-9.
167. Zhao L, Zhou S, Gustafsson JÅ. Nuclear receptors: recent drug discovery for cancer therapies. Endocr Rev 2019;40:1207-49.
168. Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov 2017;16:19-34.
169. Marciano DP, Chang MR, Corzo CA, et al. The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARγ, RORs, and Rev-erbs. Cell Metab 2014;19:193-208.
170. McKenna NJ. Research resources for nuclear receptor signaling pathways. Mol Pharmacol 2016;90:153-9.
171. Corona JC, Duchen MR. PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic Biol Med 2016;100:153-63.
172. Moutinho M, Codocedo JF, Puntambekar SS, Landreth GE. Nuclear receptors as therapeutic targets for neurodegenerative diseases: lost in translation. Annu Rev Pharmacol Toxicol 2019;59:237-61.
173. Kim CH, Han BS, Moon J, et al. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease. Proc Natl Acad Sci U S A 2015;112:8756-61.
174. Tong M, Dominguez C, Didsbury J, de la Monte SM. Targeting Alzheimer's disease neuro-metabolic dysfunction with a small molecule nuclear receptor agonist (T3D-959) reverses disease pathologies. J Alzheimers Dis Parkinsonism 2016;6:238.
175. Sharma RP. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr Res 2005;72:79-90.
176. Carta MG, Paribello P, Preti A. How promising is neuroactive steroid drug discovery? Expert Opin Drug Discov 2018;13:993-5.
177. Lerner V, Miodownik C, Gibel A, et al. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. J Clin Psychiatry 2013;74:1224-32.
178. Touma KTB, Zoucha AM, Scarff JR. Liothyronine for depression: a review and guidance for safety monitoring. Innov Clin Neurosci 2017;14:24-9.
180. Song X, Chen J, Zhao M, et al. Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A 2016;113:4970-5.
181. Raj GV, Sareddy GR, Ma S, et al. Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers. Elife 2017;6:e26857.
